Full Press Release Details
FRIENDSWOOD, Texas, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that its executive management is scheduled to present a company overview at the Stephens 27thAnnual Investment Conference on Wednesday, Nov. 19, 2025, at 10:00 a.m. Eastern time.
A live audio webcast of the Company’s presentation will be available by visiting Castle Biosciences’ website atir.castlebiosciences.com/events-presentations/. A replay of the webcast will be available following the conclusion of the live broadcast.
Castle will also be available for one-on-one investor meetings during the Jefferies Global Healthcare Conference, being held Nov. 18-20, 2025. Meetings may be requested exclusively through Jefferies Financial Group.
About Castle BiosciencesCastle Biosciences (Nasdaq: CSTL) is a leading diagnostics company improving health through innovative tests that guide patient care. The Company aims to transform disease management by keeping people first: patients, clinicians, employees and investors.
Castle’s current portfolio consists of tests for skin cancers, Barrett’s esophagus and uveal melanoma. Additionally, the Company has active research and development programs for tests in these and other diseases with high clinical need, including its test in development to help guide treatment decisions for patients with moderate-to-severe atopic dermatitis. To learn more, please visitwww.CastleBiosciences.comand connect with us onLinkedIn,Facebook,XandInstagram.
DecisionDx-Melanoma, DecisionDx-CMSeq, i31-SLNB, i31-ROR, DecisionDx-SCC, MyPath Melanoma, TissueCypher, DecisionDx-UM, DecisionDx-PRAME and DecisionDx-UMSeqare trademarks of Castle Biosciences, Inc.